Elbasvir and grazoprevir for the treatment of hepatitis C

被引：1
作者：
Wang, Szu-Jen [1 ,2 ]
Huang, Chung-Feng [3 ,4 ]
Yu, Ming-Lung [1 ,3 ,4 ]
机构：
[1] Kaohsiung Med Univ, Grad Inst Clin Med, Kaohsiung, Taiwan
[2] Yuans Gen Hosp, Dept Internal Med, Div Gastroenterol, Kaohsiung, Taiwan
[3] Kaohsiung Med Univ Hosp, Dept Internal Med, Hepatobiliary Div, Kaohsiung 807, Taiwan
[4] Kaohsiung Med Univ, Coll Med, Fac Internal Med, Kaohsiung, Taiwan
来源：
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2021年 / 19卷 / 09期
关键词：
Direct-acting antivirals; elbasvir; grazoprevir; hepatitis C virus; genotype; 1; or; 4; sustained viral response; efficacy; safety; tolerability; drug-drug interaction; VIRUS GENOTYPE 1; HCV NS5A INHIBITOR; INFECTION; ELBASVIR/GRAZOPREVIR; ASSOCIATION; EFFICACY; MK-8742; SAFETY; TRANSPLANTATION; COINFECTION;
D O I：
10.1080/14787210.2021.1874351
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Introduction: Hepatitis C is one of the leading causes of chronic liver disease. The direct-acting-antivirals has revolutionized the chronic hepatitis C treatment. DAAs can achieve a sustained virological response rate >95% in different populations. Area covered: This review summarizes the pharmacokinetics, pharmacodynamics, efficacy, and safety of Elbasvir/Grazoprevir (EBR/GZR). Expert opinion: EBR/GZR is a combination of NS5A and NS3/4A inhibitors. The performance in the EBR/GZR combination's safety and tolerability is appreciated in clinical treatment. EBR/GZR also has a higher barrier to resistance-associated substitutions. Based on clinical trials and real-world experience, elbasvir/grazoprevir is effective in the HCV GT1, 4 infections.
引用
收藏
页码：1071 / 1081
页数：11
相关论文
共 50 条
[41]   Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C-Viremic Donor to Uninfected Recipient Kidney Transplantation [J].
Sise, Meghan E. ;
Strohbehn, Ian A. ;
Chute, Donald F. ;
Gustafson, Jenna ;
Van Deerlin, Vivianna M. ;
Smith, Jennifer R. ;
Gentile, Caren ;
Wojciechowski, David ;
Williams, Winfred W. ;
Elias, Nahel ;
Chung, Raymond T. .
KIDNEY INTERNATIONAL REPORTS, 2020, 5 (04) :459-467
[42]   Elbasvir/grazoprevir for the treatment of hepatitis C virus infection in people with opioid use disorder [J].
Butt, Zahid A. .
AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2022, 48 (04) :379-381
[43]   Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy [J].
Sulejmani, Nimisha ;
Jafri, Syed-Mohammed .
HEPATIC MEDICINE-EVIDENCE AND RESEARCH, 2018, 10 :33-42
[44]   Limited drug-drug interaction of elbasvir/grazoprevir for chronic hepatitis C [J].
Liu, Chun-Jen ;
Tseng, Kuo-Chih ;
Lo, Ching-Chu ;
Tseng, I-Hao ;
Cheng, Pin-Nan .
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2020, 119 (05) :933-940
[45]   Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy [J].
Hezode, Christophe ;
Kwo, Paul ;
Sperl, Jan ;
Hwang, Peggy ;
Long, Jianmin ;
Talwani, Rohit ;
Robertson, Michael N. ;
Haber, Barbara A. .
INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2019, 11 :617-628
[46]   Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or-3 [J].
Yeh, Wendy W. ;
Fraser, Iain P. ;
Jumes, Patricia ;
Petry, Amelia ;
De Lepeleire, Inge ;
Robberechts, Martine ;
Reitmann, Christina ;
Van Dyck, Kristien ;
Huang, Xiaobi ;
Guo, Zifang ;
Panebianco, Deborah ;
Nachbar, Robert B. ;
O'mara, Edward ;
Wagner, John A. ;
Butterton, Joan R. ;
Dutko, Frank J. ;
Moiseev, Valentin ;
Kobalava, Zhanna ;
Hueser, Andreas ;
Visan, Sorin ;
Schwabe, Christian ;
Gane, Edward ;
Popa, Serghei ;
Ghicavii, Nelea ;
Uhle, Markus ;
Wagner, Frank .
CLINICAL THERAPEUTICS, 2018, 40 (05) :704-718
[47]   Elbasvir/Grazoprevir in Asia-Pacific/Russian Participants With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection [J].
George, Jacob ;
Burnevich, Eduard ;
Sheen, I-Shyan ;
Heo, Jeong ;
Nguyen Van Kinh ;
Tanwandee, Tawesak ;
Cheng, Pin-Nan ;
Kim, Do Young ;
Tak, Won Young ;
Kizhlo, Svetlana ;
Zhdanov, Konstantin ;
Isakov, Vasily ;
Liang, Liwen ;
Lindore, Pauline ;
Ginanni, Joy ;
Nguyen, Bach-Yen ;
Wahl, Janice ;
Barr, Eliav ;
Robertson, Michael ;
Ingravallo, Paul ;
Talwani, Rohit .
HEPATOLOGY COMMUNICATIONS, 2018, 2 (05) :595-606
[48]   Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population [J].
Kramer, Jennifer R. ;
Puenpatom, Amy ;
Cao, Yumei ;
Yu, Xian ;
El-Serag, Hashem B. ;
Kanwal, Fasiha .
AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2022, 48 (04) :445-453
[49]   Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence [J].
Morikawa, Kenichi ;
Nakamura, Akihisa ;
Shimazaki, Tomoe ;
Sakamoto, Naoya .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 :2749-2756
[50]   Grazoprevir and elbasvir: a second-generation protease inhibitor and a second-generation NS5A inhibitor in a combination regimen for treatment of chronic hepatitis C [J].
Ronsholt, Frederikke Falkencrone ;
Gerstoft, Jan .
FUTURE VIROLOGY, 2015, 10 (06) :691-698
12345